11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD)

11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD)

MPJE Core Concept: USP General Chapter <795> sets enforceable quality assurance standards for Compounded Non-Sterile Preparations (CNSPs). Compounding pharmacists must distinguish between Master Formulation Records and Compounding Records and strictly enforce federal Beyond-Use Dating (BUD) caps based on water activity and storage conditions.

---

Scope and Categorization of USP <795>

USP <795> applies to all persons who prepare compounded non-sterile preparations in healthcare settings, including community pharmacies, hospital pharmacies, and outpatient clinics. The chapter defines compounding as the process of combining, admixing, diluting, pooling, reconstituting (other than according to manufacturer instructions), or otherwise altering a drug or bulk substance to create a non-sterile preparation.

Compounding Complexity Levels

USP <795> classifies non-sterile compounding into three levels of complexity:

1. Simple Compounding: Preparing a formulation that has an official USP monograph or is derived from a peer-reviewed commercial study specifying exact ingredients, quantities, procedure, and stability data (e.g., Capped reconstitutions with additives, simple topical ointments).
2. Moderate Compounding: Preparing a formulation that requires special calculations, mixing ingredients where stability data for the specific combination is missing, or compounding transdermal gels.
3. Complex Compounding: Preparing formulations requiring specialized training, complex calculations, specialized equipment, or physical mechanisms (e.g., modified-release preparations, suppositories with complex lipid bases, troches).

---

Documentation Requirements: MFR vs. CR

Complete, traceable documentation is mandatory under USP <795>. Pharmacists must maintain two separate operational records:

1. Master Formulation Record (MFR)

The Master Formulation Record (MFR) serves as the pre-established protocol or "master recipe" for a CNSP. An MFR must be created for any non-sterile preparation compounded for multiple patients or when compounding from raw bulk active pharmaceutical ingredients (APIs). The MFR must include:

• Official name, strength, dosage form, and physical description of the CNSP.
• Complete list of all active and inactive ingredients with exact amounts, specifications, and raw material requirements.
• Equipment and compounding tools required.
• Explicit, step-by-step mixing and preparation instructions.
• Assigned Beyond-Use Date (BUD) rationale and required storage conditions.
• Detailed container-closure system specification.
• Quality control procedures (e.g., pH evaluation, visual inspection, weight variation checks).

2. Compounding Record (CR)

The Compounding Record (CR) is the actual operational log completed during or immediately after the preparation of an individual prescription or batch. It documents the physical execution of the MFR for a specific patient. The CR must contain:

• Name, strength, and dosage form of the CNSP, cross-referencing the specific MFR.
• Internal lot/control number unique to the batch.
• Names, lot numbers, and expiration dates of all raw ingredients used.
• Exact weighed or measured quantities of each component.
• Signatures or initials of the compounder and the supervising verifying pharmacist.
• Date and time of preparation and final yield.
• Assigned BUD and date of dispensing.
• Results of quality control procedures.

Default Beyond-Use Dating (BUD) Limits (USP <795> Standards)

A critical distinction tested on the MPJE is the difference between an Expiration Date and a Beyond-Use Date (BUD):

• Expiration Date: Assigned by commercial drug manufacturers based on extensive stability testing in accordance with FDA regulations.
• Beyond-Use Date (BUD): Assigned by the compounding pharmacist indicating the date or time after which a CNSP must not be used, stored, or transported. A BUD can NEVER exceed the expiration date of any individual API or raw material component used in the preparation.

In the absence of empirical, stability-indicating analytical testing for the specific formulation, pharmacists must strictly enforce the following USP <795> Default BUD Limits based on formulation type, presence of water, and storage condition:

1. Nonaqueous Formulations

• Formulation Examples: Capsules, nonaqueous powders, nonaqueous ointments, nonaqueous pastes, nonaqueous suppositories, and oil-based liquids.
• Maximum Assigned BUD: 180 days (6 months) or the earliest expiration date of any raw component, whichever is shorter.
• Storage Requirement: Controlled room temperature (20°C to 25°C / 68°F to 77°F).

2. Water-Containing Oral Formulations

• Formulation Examples: Aqueous oral solutions, oral suspensions, oral emulsions, oral gels, and aqueous oral syrups.
• Maximum Assigned BUD: 14 days when stored under refrigeration.
• Storage Requirement: Refrigerated conditions (2°C to 8°C / 36°F to 46°F).
• Rationale: Water provides an optimal environment for microbial proliferation and hydrolytic degradation. Cold storage retards microbial growth and chemical reaction rates.

3. Water-Containing Topical, Dermal & Mucosal Formulations

• Formulation Examples: Aqueous creams, lotions, topical gels, mucosal sprays, nasal drops, and rectal/vaginal aqueous preparations.
• Maximum Assigned BUD: 30 days.
• Storage Requirement: Controlled room temperature (20°C to 25°C / 68°F to 77°F).

---

Summary Matrix: USP <795> Default Beyond-Use Dates

---

Extending BUDs Beyond Default Limits

A pharmacist may assign an extended BUD exceeding the default limits ONLY IF:

1. The extension is supported by valid, published stability-indicating analytical study data for the exact formulation, container-closure, and storage condition, AND
2. For water-containing preparations, the formulation passes Antimicrobial Effectiveness Testing in accordance with USP <51> to ensure preservative efficacy.

---

Facility, Equipment & Sanitation Standards

• Compounding Space: Compounding must occur in a dedicated, designated area with smooth, non-porous, cleanable surfaces (countertops, walls, flooring) resistant to chemical degradation.
• Water Quality: Potable water must be available for hand washing. Purified Water (USP) or distilled water must be used for compounding formulations and final equipment rinsing.
• Personal Hygiene & Garbing: Personnel must wash hands up to the elbows with soap and water before compounding. Clean aprons/gowns and disposable gloves are mandatory. Hair covers and face masks must be worn when compounding powders or hazardous non-sterile preparations.